Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: iloperidone, Placebo.
- Who it may be relevant to
- Registry conditions: Hypertension, Uncontrolled Hypertension. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
Overview
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension
Interventions
- Drug iloperidone
iloperidone - Drug Placebo
placebo comparator
Primary outcome measures
- Change from baseline to treatment week 4 in SiSBP [Time frame: screening to treatment week 4]
Eligibility criteria
Inclusion criteria
- SiSBP >/= 130 mmHg despite >8 weeks treatment w/ 1 or more antihypertensive therapies
Exclusion criteria
- Confirmed Grade 3/severe hypertension (SiSBP >/= 180 mmHg, SiDBP >/= 120 mmHg), unstable cardiac disease, renal insufficiency
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
United States · 28 centers
- Vanda Investigative Site — Phoenix
- Vanda Investigative Site — Tempe
- Vanda Investigative Site — Tucson
- Vanda Investigative Site — Chula Vista
- Vanda Investigative Site — Dublin
- Vanda Investigative Site — Valencia
- Vanda Investigative Site — Walnut Creek
- Vanda Investigative Site — Doral
- … and 20 more centers
Identifiers
NCT: NCT07090161 · VP-VYV-683-2401